We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Eye Care

Journal Scan / Research · April 14, 2021

Intravitreous Anti–VEGF vs Sham Treatment for Prevention of Vision-Threatening Complications of Diabetic Retinopathy

JAMA ophthalmology

 

Additional Info

JAMA ophthalmology
Effect of Intravitreous Anti-Vascular Endothelial Growth Factor vs Sham Treatment for Prevention of Vision-Threatening Complications of Diabetic Retinopathy: The Protocol W Randomized Clinical Trial
JAMA Ophthalmol 2021 Mar 30;[EPub Ahead of Print], RK Maturi, AR Glassman, K Josic, AN Antoszyk, BA Blodi, LM Jampol, DM Marcus, DF Martin, M Melia, H Salehi-Had, CR Stockdale, OS Punjabi, JK Sun

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading